Medicines for multiple sclerosis: DMT options, monitoring, and planned transitions

Lists of MS medicines differ because countries, approval dates, and disease indications differ. A medicine used overseas is not automatically available at a Chinese hospital. Drugs within one class can also have different formulations, indications, initiation requirements, and monitoring arrangements.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

Disease-modifying therapies aim to alter relevant disease activity or progression risk. Corticosteroids for an acute relapse and medicines for spasticity, pain, urinary symptoms, or sleep address different problems. Several categories may legitimately appear in one plan, but each medicine needs a stated purpose. NICE MS management recommendations
Ocrelizumab and ofatumumab are anti-CD20 medicines encountered in MS discussions. The Chinese ocrelizumab label includes adult relapsing and primary progressive MS, with infection-related assessment and infusion-management requirements. Confirm the exact generic name, especially when translating between languages. Similar-sounding monoclonal antibody names may refer to different medicines. Chinese ocrelizumab prescribing information
Check generic name, formulation, strength, lawful supply, and agreement with the prescription. If an alternative product is proposed, ask about its basis and any training required. Similar packaging or apparently comparable quantities do not guarantee equivalent instructions, and overseas prices do not establish individual costs in China.

Quick answer

Full guide

Begin with the complete prescription: generic name, treatment purpose, reason for suitability, and the way benefit and safety will be assessed. The examples below draw on Chinese prescribing information and international regulatory sources. Actual use must be checked against the current information applicable where treatment will occur.

Distinguish DMT from attack and symptom treatment

Disease-modifying therapies aim to alter relevant disease activity or progression risk. Corticosteroids for an acute relapse and medicines for spasticity, pain, urinary symptoms, or sleep address different problems. Several categories may legitimately appear in one plan, but each medicine needs a stated purpose. NICE MS management recommendations

Keep a list organized by purpose, duration, and prescribing clinician. If drowsiness, fatigue, or another problem develops, the team can review possible medicine effects alongside disease and other causes. Stopping the most expensive item is not a reliable way to identify the source.

Update safety knowledge even for established injections

Long experience with treatments such as interferons does not establish that they are the best fit for every patient. Continuing treatment depends on activity, tolerance, and individual priorities. The AAN guideline addresses starting, switching, and monitoring principles; it is not a final 2026 inventory of every product and safety development. AAN DMT practice guideline

In January 2025, the FDA added a boxed warning for anaphylaxis with glatiramer acetate. A serious reaction can occur after a long period of use. Breathing difficulty or swelling of the face, lips, or throat requires emergency attention; worsening or persistent post-injection symptoms should not simply be assumed to be a temporary familiar reaction. FDA glatiramer safety communication

Do not independently try another injection after a suspected serious reaction. The prescriber must determine whether resumption is appropriate and whether another clear cause exists. This overseas warning concerns drug safety; it does not independently establish Chinese approval or supply.

Teriflunomide requires liver and reproductive planning

Sanofi's publicly available Chinese information was revised in August 2025 and includes adult relapsing MS and specified paediatric relapsing-remitting use. It contains prominent hepatotoxicity and embryo-fetal toxicity warnings, with relevant assessment before and during treatment. Disclose liver disease, pregnancy plans, or possible pregnancy before prescribing. Chinese teriflunomide information

Elimination after stopping can be slow. Some circumstances require a clinician-managed accelerated elimination procedure and testing. The last tablet date is therefore not automatically the date when conception or another regimen becomes appropriate. Men's reproductive plans also require discussion under the applicable prescribing information.

Report jaundice, markedly dark urine, persistent nausea, or other concerning changes promptly. A normal previous test does not replace future monitoring. Show the team the ingredients of supplements, herbal products, and other medicines so that relevant combined risks can be assessed.

Dimethyl fumarate requires attention to lymphocytes

Regulatory information for dimethyl fumarate requires blood-count assessment, including lymphocytes. Risks include lymphopenia and rare but serious progressive multifocal leukoencephalopathy, or PML. It is inaccurate to reduce vigilance to a rule that risk exists only when counts are extremely low. EMA dimethyl fumarate product information

Identify who follows the trend rather than merely checking whether each result is flagged. Persistent new changes in cognition, vision, coordination, or limb function need timely review for MS, infection, or another explanation. Similarity to a previous attack is not a reason to self-treat with steroids.

Gastrointestinal symptoms or flushing also deserve discussion when they affect tolerability. Continuing, pausing, or changing treatment requires consideration of severity and disease control. Neither unplanned interruption after one unpleasant episode nor concealing a substantial problem helps the team manage treatment well.

S1P medicines can have specific initiation and restart rules

Fingolimod and siponimod affect lymphocyte trafficking, but their requirements are not identical. EMA siponimod information updated in 2026 includes CYP2C9 genotyping, restrictions for particular genotypes, and attention to cardiac, infectious, and other risks. EMA Mayzent information

CYP2C9 assessment informs use of that medicine; it is not a genetic test diagnosing MS. Ask about initiation monitoring and how an interruption changes restarting. Having taken a medicine previously does not prove that restarting after a gap is the same as taking an uninterrupted maintenance dose.

The FDA has warned about severe disease worsening after fingolimod cessation. Pregnancy planning, switching, or a threatened supply interruption should therefore prompt advance coordination. Concern about adverse effects is a reason to discuss the plan, not to assume that abrupt independent cessation is safer. FDA fingolimod stopping warning

Anti-CD20 products still require individual checks

Ocrelizumab and ofatumumab are anti-CD20 medicines encountered in MS discussions. The Chinese ocrelizumab label includes adult relapsing and primary progressive MS, with infection-related assessment and infusion-management requirements. Confirm the exact generic name, especially when translating between languages. Similar-sounding monoclonal antibody names may refer to different medicines. Chinese ocrelizumab prescribing information

For ofatumumab, verify the MS formulation, administration process, and training. EMA information highlights hepatitis B reactivation and the need for screening and appropriate specialist involvement. Do not transfer an oncology regimen for the same ingredient into MS care. Home administration does not eliminate the need for safety assessment. EMA ofatumumab product information

Provide previous hepatitis results, recurrent-infection history, and other immune-treatment exposures. An abnormal screening result requires clinical interpretation: whether treatment is contraindicated, whether a problem can be managed, and what follow-up is needed. Vaccination and subsequent monitoring must fit the chosen treatment.

BTK developments in 2026 do not establish class-wide availability

The EU authorized tolebrutinib as Cenrifki in 2026 for adults with secondary progressive MS without relapses in the preceding two years. Serious liver injury makes assessment and continued monitoring important conditions of use. An oral formulation does not mean that treatment consists only of collecting tablets. EMA Cenrifki authorization and product information

The FDA issued a complete response letter in December 2025 addressing liver injury and benefit-risk concerns. This decision and the subsequent EU authorization must be described separately. Neither establishes Chinese approval, and findings for another investigational BTK inhibitor do not authorize an entire class. FDA tolebrutinib complete response letter

When reading an announcement, identify the disease population, jurisdiction, and evidence date before considering personal relevance. A research signal, a marketing authorization, and a hospital's ability to provide care are separate conditions. Verify them before making inflexible travel arrangements around a drug name.

Vaccination and reproductive plans affect the schedule

Immune therapies can affect vaccine selection, timing, or response. Assemble previous vaccination records and disclose travel plans early. ECTRIMS and EAN recommendations address treatment-specific circumstances; all people with MS do not share an identical immunosuppression status. MS vaccination consensus

The 2026 pregnancy consensus update also considers treatment durability and disease activity after withdrawal during pregnancy and postpartum. The prescriber should connect personal plans with disease activity and Chinese product information. Pregnancy-related concerns should not become an instruction to stop all treatment without review. 2026 pregnancy and MS consensus

Describe a scheduling conflict concretely: inability to obtain blood tests, a near-term conception plan, or lack of a local refill service. These are meaningful treatment-selection factors. Raising them before an interruption gives the team a chance to plan an alternative arrangement.

Give stopping and switching a responsible clinician

A switch may reflect insufficient disease control, adverse effects, reproductive plans, or access changes. The transition plan should state how the existing treatment ends, when another begins, what tests are required, and who handles symptoms during the interval. Residual effects and withdrawal risks differ, so one universal gap is inappropriate.

If treatment is missed, retain the actual last date and dose and seek medicine-specific guidance from the prescriber or pharmacist. Doubling doses, extending intervals, or borrowing medicine can disrupt safety and interpretation. When institutions change, transfer the reason and chronology so that responsibility does not disappear between services.

Verify the product and continuing service in China

Check generic name, formulation, strength, lawful supply, and agreement with the prescription. If an alternative product is proposed, ask about its basis and any training required. Similar packaging or apparently comparable quantities do not guarantee equivalent instructions, and overseas prices do not establish individual costs in China.

Confirm medicine, administration, laboratory, and review costs separately, along with supply after leaving China. Bring actual use records, recent results, and adverse experiences to reviews. Reliable medicine management includes keeping the responsible clinician informed about how the plan is being carried out.